Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
This approval is based on data from the Phase 2 KEYNOTE-629 trial, in which KEYTRUDA demonstrated meaningful efficacy and durability of response, with an objective response rate (ORR) of 34% (95% CI, 25-44), including a complete response rate of 4% and a partial response rate of 31%. Among responding patients, 69% had ongoing responses of six months or longer. After a median follow-up time of 9.5 months, the median duration of response (DOR) had not been reached (range, 2.7 to 13.1+ months).
CUTANEOUS SQUAMOUS CELL CARCINOMA IS THE SECOND MOST COMMON FORM OF SKIN CANCER,” SAID DR. JONATHAN CHENG, VICE PRESIDENT, CLINICAL RESEARCH, MERCK RESEARCH LABORATORIES. “IN KEYNOTE-629, TREATMENT WITH KEYTRUDA RESULTED IN CLINICALLY MEANINGFUL AND DURABLE RESPONSES. TODAY’S APPROVAL IS GREAT NEWS FOR PATIENTS WITH CSCC AND FURTHER DEMONSTRATES OUR COMMITMENT TO BRINGING NEW TREATMENT OPTIONS TO PATIENTS WITH ADVANCED, DIFFICULT-TO-TREAT CANCERS.